GlaxoSmithKline PO Box 13398 Five Moore Drive Research Triangle Park IMPORTANT REVISIONS TO PRESCRIBING INFORMATION FOR SEREVENT® (salmeterol xinafoate) AND ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)
GlaxoSmithKline is writing to you as a prescriber of SEREVENT and/or ADVAIR, to communicateimportant new revisions to the prescribing information for SEREVENT and ADVAIR, which includes the following boxed warning. BOXED WARNING FOR SEREVENT AND ADVAIR WARNING: Data from a large placebo-controlled US study that compared the safety of salmeterol (SEREVENT Inhalation Aerosol) or placebo added to usual asthma therapy showed a small but significant increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13,174 patients treated for 28 weeks) versus those on placebo (4 out of 13,179). Subgroup analyses suggest the risk may be greater in African-American patients compared to Caucasians. BACKGROUND
In January, GSK communicated findings from an interim analysis of a large study investigating the use of SEREVENT in patients with asthma. This analysis reported an association between SEREVENTand rare, but potentially serious, asthma-related events. Since that time, GlaxoSmithKline has beenreviewing the data with the Food and Drug Administration (FDA) and has subsequently updated theprescribing information for SEREVENT and ADVAIR; salmeterol being the active component ofSEREVENT and one of the active components of ADVAIR. SMART Safety Study
In July 1996, GSK initiated the Salmeterol Multi-center Asthma Research Trial (SMART), a 28-weeksafety study comparing SEREVENT and placebo in the treatment of asthma. In addition to theirprescribed asthma therapy, patients in one arm of the study received 42 mcg of SEREVENT (N=13,174)twice a day through an MDI, and patients in the other arm received placebo (N=13,179). The primaryendpoint of SMART was the combined number of respiratory related deaths or respiratory related life-threatening experiences (intubations and mechanical ventilation). Other endpoints included asthma-related life-threatening experiences (including deaths) and asthma-related deaths alone. A plannedinterim analysis was conducted when approximately half of the intended number of patients wereenrolled. Even though SMART did not reach predetermined stopping criteria, the study was stoppeddue to findings in African-American patients and difficulties with enrollment.
The analysis of SMART showed no significant difference for the primary endpoint for the totalpopulation. However, a higher number of asthma-related deaths or life-threatening experiences (36 vs. 23) and a higher number of asthma-related deaths (13 vs. 4) occurred in the patients treatedwith SEREVENT Inhalation Aerosol. No significant increase was observed in respiratory or asthma-related episodes, including deaths, in Caucasian patients. In African-Americans, the study showed asmall, though statistically significantly greater number of primary events (20 vs. 7), asthma-relateddeaths or life-threatening experiences (19 vs. 4), and asthma-related deaths (8 vs. 1) in patients takingSEREVENT Inhalation Aerosol compared to those taking placebo. However, due to the low rate ofprimary events in the study, the findings of the planned interim analysis were not conclusive.
In addition to the boxed warning, other sections of the package insert for SEREVENT and ADVAIR(Clinical Trials, Warnings, and Information for Patients) have been updated to include the results fromSMART and the following additional information:
• Patients should not stop SEREVENT or ADVAIR therapy for asthma or SEREVENT for COPD without
physician/provider guidance since symptoms may recur after discontinuation.
• Given the similar basic mechanisms of action of beta -agonists, it is possible that the findings seen in
SMART may be consistent with a class effect.
• Data from SMART are not adequate to determine whether concurrent use of inhaled corticosteroids
such as fluticasone propionate, a component of ADVAIR DISKUS, provides protection from this risk. Therefore, it is not known whether the findings seen with SEREVENT would apply to ADVAIR. Important Advice for Managing Your Patients
GSK believes it is important to reiterate and reinforce advice for the management of patients asestablished in the prescribing information for SEREVENT and ADVAIR.
• Patients who are currently taking SEREVENT or ADVAIR should not discontinue their
treatment without first consulting a physician. Abruptly stopping medications may result in acutely deteriorating asthma control, which may be life-threatening.
• SEREVENT is not a replacement for inhaled corticosteroids, which should be continued at the same
dose, and not stopped or reduced, when treatment with salmeterol is initiated.
• SEREVENT or ADVAIR should not be initiated in patients with significantly worsening or acutely
deteriorating asthma, which may be life-threatening.
• SEREVENT or ADVAIR should not be used to treat acute symptoms.
• Patients on SEREVENT or ADVAIR must also have a short-acting bronchodilator (e.g., albuterol) for
• The increased need for using the short-acting bronchodilator is a sign of deteriorating asthma.
• Patients should be educated to recognize the signs of deteriorating asthma control and the need to
seek medical attention promptly in such circumstances.
If you have any questions regarding the use of SEREVENT or ADVAIR in patients with asthma, pleasecontact our customer response center at 1-888-825-5249.
It is important that you forward any adverse event information associated with the use of SEREVENTor ADVAIR to GlaxoSmithKline at 1-888-825-5249. You can also report this information directly to theFDA via the MedWatch system at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail (using a postage-paid form) to MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20857, or by the internet atwww.FDA.gov/medwatch.
Enclosed, for your information, is a copy of the package inserts for SEREVENT DISKUS and ADVAIR DISKUS.
Kathleen A. Rickard, M.D. Vice PresidentRespiratory, Clinical Development and Medical Affairs
Material Safety Data Sheet Revision: 10/17/2005 Hazard information is provided for compliance with both the UK Chemicals(Hazard Information and Packaging) (CHIP) Regulations and the US HazardCommunication Standard (HCS) IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND COMPANY Emergency Contact : USB Corporation, 26111 Miles Road, Cleveland, Ohio 44128 Phone: (216) 765-5000 Chemt
What is Papilledema? ♦ A floating black speck, resulting from an Papilledema can narrow the range of your This condition is known as pseudotumor be-enlarged blind spot in the field of vision, usually peripheral vision. Your doctor may check your cause it exhibits the same symptoms caused by a apilledema is a rare condition that involves the in both eyes. Everyone has a “blind